Small interfering RNA-based nanotherapeutics for treating skin-related diseases

References

• Stephenson ML, Zamecnik PC. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci U S A. 1978;75:285‒288.
   Web of Science ®Google Scholar
• Yamada Y. Nucleic acid drugs-Current status, issues, and expectations for exosomes. Cancers (Basel). 2021;13:5002.
   PubMed Web of Science ®Google Scholar
• Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020;19:673‒694. DOI:10.1038/s41573-020-0075-7.
   Web of Science ®Google Scholar
• Mir C, Garcia-Mayea Y, LLeonart ME. Targeting the “undruggable”: rNA-binding proteins in the spotlight in cancer therapy. Semin Cancer Biol. 2022;86:69‒83.
   Web of Science ®Google Scholar
• Slack FJ, Chinnaiyan AM. The role of non-coding RNAs in oncology. Cell. 2019;179:1033–1055.
   PubMed Web of Science ®Google Scholar
• Kim YK. RNA therapy: rich history, various applications and unlimited future prospects. Exp Mol Med. 2022;54:455–465. DOI:10.1038/s12276-022-00757-5.
   PubMed Web of Science ®Google Scholar
• Flohr C, Hay R. Putting the burden of skin diseases on the global map. Br J Dermatol. 2021;184:189–190.
   PubMed Web of Science ®Google Scholar
• Bellefroid C, Lechanteur A, Evrard B, et al. Lipid gene nanocarriers for the treatment of skin diseases: current state-of-the-art. Eur J Pharm Biopharm. 2019;137:95–111.
   PubMed Web of Science ®Google Scholar
• Ain QU, Campos EVR, Huynh A, et al. Gene delivery to the skin-How far have we come? Trends Biotechnol. 2021;39:474–487. DOI:10.1016/j.tibtech.2020.07.012.
   PubMed Web of Science ®Google Scholar
• Damase TR, Sukhovershin R, Boada C, et al. The limitless future of RNA therapeutics. Front Bioeng Biotechnol. 2021;9:628137.
   PubMed Web of Science ®Google Scholar
• O’Sullivan J, Muñoz-Muñoz J, Turnbull G, et al. Beyond GalNAc! Drug delivery systems comprising complex oligosaccharides for targeted use of nucleic acid therapeutics. RSC Adv. 2022;12:20432.
   PubMed Web of Science ®Google Scholar
• Mainini F, Eccles MR. Lipid and polymer-based nanoparticle siRNA delivery systems for cancer therapy. Molecules. 2020;25:2692.
   PubMed Web of Science ®Google Scholar
• Aljuffali IA, Lin CH, Yang SC, et al. Nanoencapsulation of topically applied tea catechins for enhancing skin absorption and therapeutic efficacy. AAPS Pharm Sci Tech. 2022;23:187.
   PubMed Web of Science ®Google Scholar
• Tieu T, Wei Y, Cifuentes-Rius A, et al. Overcoming barriers: clinical translation of siRNA nanomedicines. Adv Ther. 2021;4:2100108. DOI:10.1002/adtp.202100108.
   Google Scholar
• Kim B, Park JH, Sailor MJ. Rekindling RNAi therapy: materials design requirements for in vivo siRNA delivery. Adv Mater. 2019;31:e1903637.
   PubMed Web of Science ®Google Scholar
• Wu Z, Li T. Nanoparticle-mediated cytoplasmic delivery of messenger RNA vaccines: challenges and future perspectives. Pharm Res. 2021;38:473–478.
   PubMed Web of Science ®Google Scholar
• Sousa de Almeida M, Susnik E, Drasler B, et al. Understanding nanoparticle endocytosis to improve targeting in nanomedicine. Chem Soc Rev. 2021;50:5397–5434. DOI:10.1039/D0CS01127D.
   PubMed Web of Science ®Google Scholar
• Milane L, Amiji M. Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine. Drug Deliv Transl Res. 2021;11:1309–1315.
   PubMed Web of Science ®Google Scholar
• Steffens RC, Wagner E. Directing the way—Receptor and chemical targeting strategies for nucleic acid delivery. Pharm Res. 2022;40(1):47–76.
   PubMed Web of Science ®Google Scholar
• Benson HAE, Grice JE, Mohammed Y, et al. Topical and transdermal drug delivery: from simple potions to smart technologies. Curr Drug Deliv. 2019;16:444–460.
   PubMed Web of Science ®Google Scholar
• Gupta R, Rai B. In-silico design of nanoparticles for transdermal drug delivery application. Nanoscale. 2018;10:4940–4951.
   PubMed Web of Science ®Google Scholar
• Larese Filon F, Mauro M, Adami G, et al. Nanoparticles skin absorption: new aspects for a safety profile evaluation. Regul Toxicol Pharmacol. 2015;72:310–322.
   PubMed Web of Science ®Google Scholar
• Souto EB, Macedo AS, Dias-Ferreira J, et al. Elastic and ultradeformable liposomes for transdermal delivery of active pharmaceutical ingredients (APIs). Int J Mol Sci. 2021;22:9743.
   PubMed Web of Science ®Google Scholar
• Kulkarni JA, Cullis PR, van der Meel R. Lipid nanoparticles enabling gene therapies: from concepts to clinical utility. Nucleic Acid Ther. 2018;28:146–157.
   PubMed Web of Science ®Google Scholar
• Valcourt DM, Harris J, Riley RS, et al. Advances in targeted nanotherapeutics: from bioconjugation to biomimicry. Nano Res. 2018;11:4999–5016. DOI:10.1007/s12274-018-2083-z.
   PubMed Web of Science ®Google Scholar
• Ranasinghe P, Addison ML, Dear JW, et al. Small interfering RNA: discovery, pharmacology and clinical development-An introductory review. Br J Pharmacol. 2022. DOI:10.1111/bph.15972
   PubMed Web of Science ®Google Scholar
• Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391:806–811.
   PubMed Web of Science ®Google Scholar
• Ashrafizadeh M, Zarrabi A, Hushmandi K, et al. Progress in natural compounds/siRNA co-delivery employing nanovehicles for cancer therapy. ACS Comb Sci. 2020;22:669–700.
   PubMed Web of Science ®Google Scholar
• Aljuffali IA, Lin YK, Fang JY. Noninvasive approach for enhancing small interfering RNA delivery percutaneously. Expert Opin Drug Deliv. 2016;13:265–280.
   PubMed Web of Science ®Google Scholar
• Alshaer W, Zureigat H, Al Karaki A, et al. siRNA: mechanism of action, challenges, and therapeutic approaches. Eur J Pharmacol. 2021;905:174178.
   PubMed Web of Science ®Google Scholar
• Aimo A, Castiglione V, Rapezzi C, et al. RNA-targeting and gene editing therapies for transthyretin amyloidosis. Nat Rev Cardiol. 2022;19:655–667.
   PubMed Web of Science ®Google Scholar
• Friedrich M, Aigner A. Therapeutic siRNA: state-of-the-art and future perspectives. BioDrugs. 2022;36:549–571.
   PubMed Web of Science ®Google Scholar
• Kalita T, Dezfouli SA, Pandey LM, et al. siRNA functionalized lipid nanoparticles (LNPs) in management of diseases. Pharmaceutics. 2022;14:2520.
   PubMed Web of Science ®Google Scholar
• Subhan MA, Torchilin VP. siRNA based drug design, quality, delivery and clinical translation. Nanomed Nanotechnol Biol Med. 2020;29:102239.
   PubMed Web of Science ®Google Scholar
• Hald Albertsen C, Kulkarni JA, Witzigmann D, et al. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv Drug Deliv Rev. 2022;188:114416.
   PubMed Web of Science ®Google Scholar
• Griffiths G, Gruenberg J, Marsh M, et al. Nanoparticle entry into cells; the cell biology weak link. Adv Drug Deliv Rev. 2022;188:114403.
   PubMed Web of Science ®Google Scholar
• Mendes BB, Conniot J, Avital A, et al. Nanodelivery of nucleic acids. Nat Rev Methods Primers. 2022;2:24.
   PubMedGoogle Scholar
• Sharma AR, Lee YH, Bat-Ulzii A, et al. Recent advances of metal-based nanoparticles in nucleic acid delivery for therapeutic applications. J Nanobiotechnol. 2022;20:501.
   PubMed Web of Science ®Google Scholar
• Schade A, Delyagina E, Scharfenberg D, et al. Innovative strategy for microRNA delivery in human mesenchymal stem cells via magnetic nanoparticles. Int J Mol Sci. 2013;14:10710–10726.
   PubMed Web of Science ®Google Scholar
• Yin PT, Shah BP, Lee KB. Combined magnetic nanoparticle-based microRNA and hyperthermia therapy to enhance apoptosis in brain cancer cells. Small. 2014;10:4106–4112.
   PubMed Web of Science ®Google Scholar
• Eloy JO, Petrilli R, Lopez RFV, et al. Stimuli-responsive nanoparticles for siRNA delivery. Curr Pharm Des. 2015;21:4131–4144.
   PubMed Web of Science ®Google Scholar
• Marques TS, Śmiałek MA, Schürmann R, et al. Decomposition of halogenated nucleobases by surface plasmon resonance excitation of gold nanoparticles. Eur Phys J D. 2020;74:222.
   Web of Science ®Google Scholar
• Gomes PJ, Ferraria AM, Botelho Do Rego AM, et al. Energy thresholds of DNA damage induced by UV radiation: an XPS study. J Phys Chem B. 2015;119:5404–5411.
   PubMed Web of Science ®Google Scholar
• Graczyk A, Pawlowska R, Chworos A. Gold nanoparticles as carriers for functional RNA nanostrucrures. Bioconjug Chem. 2021;32:1667–1674.
   PubMed Web of Science ®Google Scholar
• Luther DC, Huang R, Jeon T, et al. Delivery of drugs, proteins, and nucleic acids using inorganic nanoparticles. Adv Drug Deliv Rev. 2020;156:188–213. DOI:10.1016/j.addr.2020.06.020.
   PubMed Web of Science ®Google Scholar
• Paiva-Santos AC, Herdade AM, Guerra C, et al. Plant-mediated green synthesis of metal-based nanoparticles for dermopharmaceutical and cosmetic applications. Int J Pharm. 2021;597:120311.
   PubMed Web of Science ®Google Scholar
• Alalaiwe A, Lin YC, Lin CF, et al. TiO2-embedded mesoporous silica with lower porosity is beneficial to adsorb the pollutants and retard UV filter absorption: a possible application for outdoor skin protection. Eur J Pharm Sci. 2023;180:106344.
   PubMed Web of Science ®Google Scholar
• Vallet-Regí M, Schüth F, Lozano D, et al. Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades? Chem Soc Rev. 2022;51:5365–5451.
   PubMed Web of Science ®Google Scholar
• Cha W, Fan R, Miao Y, et al. Mesoporous silica nanoparticles as carriers for intracellular delivery of nucleic acids and subsequent therapeutic applications. Molecules. 2017;22:782.
   PubMed Web of Science ®Google Scholar
• Tivnan A, Orr WS, Gubala V, et al. Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS ONE. 2012;7:e38129.
   PubMed Web of Science ®Google Scholar
• Bertucci A, Prasetyanto EA, Septiadi D, et al. Combined delivery of temozolomide and anti-miR221 PNA using mesoporous silica nanoparticles induces apoptosis in resistant glioma cells. Small. 2015;11:5687–5695.
   PubMed Web of Science ®Google Scholar
• Kolimi P, Narala S, Youssef AAA, et al. A systemic review on development of mesoporous nanoparticles as a vehicle for transdermal drug delivery. Nanotheranostics. 2023;7:70–89.
   PubMedGoogle Scholar
• Ghasemiyeh P, Mohammadi-Samani S. Potential of nanoparticles as permeation enhancers and targeted delivery options for skin: advantages and disadvantages. Drug Des Devel Ther. 2020;14:3271–3289. DOI:10.2147/DDDT.S264648.
   PubMed Web of Science ®Google Scholar
• Lin YK, Yang SC, Hsu CY, et al. The antibiofilm nanosystems for improved infection inhibition of microbes in skin. Molecules. 2021;26:6392.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Tsai PC, Ramezanli T, et al. Polymeric nanoparticles-based topical delivery systems for the treatment of dermatological diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013;5:205–218.
   PubMed Web of Science ®Google Scholar
• Mohammadi Z, Eini M, Rastegari A, et al. Chitosan as a machine for biomolecule delivery: a review. Carbohydr Polym. 2021;256:117414.
   PubMed Web of Science ®Google Scholar
• Fan Y, Liu Y, Wu Y, et al. Natural polysaccharides based self-assembled nanoparticles for biomedical applications-A review. Int j biol macromol. 2021;192:1240–1255.
   PubMed Web of Science ®Google Scholar
• Wang S, Zhang J, Wang Y, et al. Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy. Nanomedicine. 2016;12:411–420.
   PubMed Web of Science ®Google Scholar
• Abbasi E, Aval SF, Akbarzadeh A, et al. Dendrimers: synthesis, applications, and properties. Nanoscale Res Lett. 2014;9:247.
   PubMed Web of Science ®Google Scholar
• Dave K, Krishna Venuganti VV. Dendritic polymers for dermal drug delivery. Ther Deliv. 2017;8:1077–1096.
   PubMed Web of Science ®Google Scholar
• Choudhury H, Pandey M, Mohgan R, et al. Dendrimer-based delivery of macromolecules for the treatment of brain tumor. Biomater Adv. 2022;141:213118.
   PubMedGoogle Scholar
• Butt AM, Abdullah N, Rani NNIM, et al. Endosomal escape of bioactives deployed via nanocarriers: insights into the design of polymeric micelles. Pharm Res. 2022;39:1047–1064.
   PubMed Web of Science ®Google Scholar
• Antimisiaris SG, Marazioti A, Kannavou M, et al. Overcoming barriers by local drug delivery with liposomes. Adv Drug Deliv Rev. 2021;174:53–86.
   PubMed Web of Science ®Google Scholar
• Hsu CY, Yang SC, Sung CT, et al. Anti-MRSA malleable liposomes carrying chloramphenicol for ameliorating hair follicle targeting. Int J Nanomed. 2017;12:8227–8238.
   PubMed Web of Science ®Google Scholar
• Akram MW, Jamshaid H, Rehman FU, et al. Transfersomes: a revolutionary nanosystem for efficient transdermal drug delivery. AAPS Pharm Sci Tech. 2021;23:7.
   PubMed Web of Science ®Google Scholar
• Paiva-Santos AC, Silva AL, Guerra C, et al. Ethosomes as nanocarriers for the development of skin delivery formulations. Pharm Res. 2021;38:947–970.
   PubMed Web of Science ®Google Scholar
• Geusens B, Van Gele M, Braat S, et al. Flexible nanosomes (SECosomes) enable efficient siRNA delivery in cultured primary skin cells and in the viable epidermis of ex vivo human skin. Adv Funct Mater. 2010;20:4077–4090.
   Web of Science ®Google Scholar
• Ewert KK, Scodeller P, Simón-Gracia L, et al. Cationic liposomes as vectors for nucleic acid and hydrophobic drug therapeutics. Pharmaceutics. 2021;13:1365.
   PubMed Web of Science ®Google Scholar
• Malone RW, Felgner PL, Verma IM. Cationic liposome-mediated RNA transfection. Proc Natl Acad Sci U S A. 1989;86:6077–6081.
   PubMed Web of Science ®Google Scholar
• Santos AC, Morais F, Simões A, et al. Nanotechnology for the development of new cosmetic formulations. Expert Opin Drug Deliv. 2019;16:313–330.
   PubMed Web of Science ®Google Scholar
• Rai VK, Mishra N, Yadav KS, et al. Nanoemulsion as pharmaceutical carrier for dermal and transdermal drug delivery: formulation development, stability issues, basic considerations and applications. J Control Release. 2018;270:203–225.
   PubMed Web of Science ®Google Scholar
• Souto EB, Fangueiro JF, Fernandes AR, et al. Physicochemical and biopharmaceutical aspects influencing skin permeation and role of SLN and NLC for skin drug delivery. Heliyon. 2022;8:e08938.
   PubMed Web of Science ®Google Scholar
• Lee SWL, Paoletti C, Campisi M, et al. MicroRNA delivery through nanoparticles. J Control Release. 2019;313:80–95.
   PubMed Web of Science ®Google Scholar
• Madheswaran T, Kandasamy M, Bose RJ, et al. Current potential and challenges in the advances of liquid crystalline nanoparticles as drug delivery systems. Drug Discov Today. 2019;24:1405–1412.
   PubMed Web of Science ®Google Scholar
• Silvestrini AVP, Caron AL, Viegas J, et al. Advances in lyotropic liquid crystal systems for skin drug delivery. Expert Opin Drug Deliv. 2020;17:1781–1805.
   PubMed Web of Science ®Google Scholar
• He S, Fan W, Wu N, et al. Lipid-based liquid crystalline nanoparticles facilitate cytosolic delivery of siRNA via structural transformation. Nano Lett. 2018;18:2411–2419.
   PubMed Web of Science ®Google Scholar
• Lefèvre-Utile A, Braun C, Haftek M, et al. Five functional aspects of the epidermal barrier. Int J Mol Sci. 2021;22:11676.
   PubMed Web of Science ®Google Scholar
• Ganesan P, Choi DK. Current application of phytocompound-based nanocosmeceuticals for beauty and skin therapy. Int J Nanomed. 2016;11:1987–2007.
   PubMed Web of Science ®Google Scholar
• Fang CL, Aljuffali IA, Li YC, et al. Delivery and targeting of nanoparticles into hair follicles. Ther Deliv. 2014;5:991–1006.
   PubMedGoogle Scholar
• Patzelt A, Lademann J. Recent advances in follicular drug delivery of nanoparticles. Expert Opin Drug Deliv. 2020;17:49–60. DOI:10.1080/17425247.2020.1700226.
   PubMed Web of Science ®Google Scholar
• Zorn-Kruppa M, Vidal-Y-Sy S, Houdek P, et al. Tight junction barriers in human hair follicles−Role of claudin-1. Sci Rep. 2018;8:12800.
   PubMed Web of Science ®Google Scholar
• Filon FL, Crosera M, Adami G, et al. Human skin penetration of gold nanoparticles through intact and damaged skin. Nanotoxicology. 2011;5:493–501.
   PubMed Web of Science ®Google Scholar
• Cui M, Wiraja C, Chew SWT, et al. Nanodelivery systems for topical management of skin disorders. Mol Pharm. 2021;18:491–505. DOI:10.1021/acs.molpharmaceut.0c00154.
   PubMedGoogle Scholar
• Zheng D, Giljohann DA, Chen DL, et al. Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation. Proc Natl Acad Sci U S A. 2012;109:11975–11980.
   PubMed Web of Science ®Google Scholar
• Williams SC. Spherical nucleic acids: a whole new ball game. Proc Natl Acad Sci U S A. 2013;110:13231–13233.
   PubMed Web of Science ®Google Scholar
• Jacobson GB, Gonzalez-Gonzalez E, Spitler R, et al. Biodegradable nanoparticles with sustained release of functional siRNA in skin. J Pharm Sci. 2010;99:4261–4266.
   PubMed Web of Science ®Google Scholar
• de Carvalho Vicentini FT, Depieri LV, Polizello AC, et al. Liquid crystalline phase nanodispersions enable skin delivery of siRNA. Eur J Pharm Biopharm. 2013;83:16–24.
   PubMed Web of Science ®Google Scholar
• Zakrewsky M, Mitragotri S. Therapeutic RNAi robed with ionic liquid moieties as a simple, scalable prodrug platform for treating skin disease. J Control Release. 2016;242:80–88.
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Armstrong AW, Gudjonsson JE, et al. Psoriasis. Lancet. 2021;397:1301‒1315.
   PubMed Web of Science ®Google Scholar
• Huang TH, Lin CF, Alalaiwe A, et al. Apoptotic or antiproliferative activity of natural products against keratinocytes for the treatment of psoriasis. Int J Mol Sci. 2019;20:2558.
   PubMed Web of Science ®Google Scholar
• Nemati H, Ghahramani MH, Faridi-Majidi R, et al. Using siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation in psoriasis. J Control Release. 2017;268:259‒268.
   PubMed Web of Science ®Google Scholar
• Lee WR, Chou WL, Lin ZC, et al. Laser-assisted nanocarrier delivery to achieve cutaneous siRNA targeting for attenuating psoriasiform dermatitis. J Control Release. 2022;347:590–606.
   PubMed Web of Science ®Google Scholar
• Pandi P, Jain A, Kommineni N, et al. Dendrimer as a new potential carrier for topical delivery of siRNA: a comparative study of dendriplex vs. lipoplex for delivery of TNF-α siRNA. Int J Pharm. 2018;550:240‒250.
   PubMedGoogle Scholar
• Bracke S, Carretero M, Guerrero-Aspizua S, et al. Targeting silencing of DEFB4 in a bioengineered skin-humanized mouse model for psoriasis: development of siRNA SECosomes-based novel therapies. Exp Dermatol. 2014;23:199‒201.
   PubMed Web of Science ®Google Scholar
• Marepally S, Boakye CH, Patel AR, et al. Topical administration of dual siRnas using fusogenic lipid nanoparticles for treating psoriatic-like plaques. Nanomedicine. 2014;9:2157‒2174.
   PubMed Web of Science ®Google Scholar
• Viegas JSR, Praça FG, Caron AL, et al. Nanostructured lipid carrier co-delivering tacrolimus and TNF-α siRNA as an innovate approach to psoriasis. Drug Deliv Transl Res. 2020;10:646‒660.
   Web of Science ®Google Scholar
• Desai PR, Marepally S, Patel AR, et al. Topical delivery of anti-TNF-α siRNA and capsaicin via novel lipid-polymer hybrid nanoparticles efficiently inhibits skin inflammation in vivo. J Control Release. 2013;170:51‒63.
   PubMed Web of Science ®Google Scholar
• Petrilli R, Eloy JO, Praça FS, et al. Liquid crystalline nanodispersions functionalized with cell-penetrating peptides for topical delivery of short-interfering RNAs: a proposal for silencing a pro-inflammatory cytokine in cutaneous diseases. J Biomed Nanotechnol. 2016;12:1063‒1075.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Yamasaki K. Psoriasis and antimicrobial peptides. Int J Mol Sci. 2020;21:6791.
   PubMed Web of Science ®Google Scholar
• Kim CS, Kawada T, Kim BS, et al. Capsaicin exhibits anti-inflammatory property by inhibiting IκB-a degradation in LPS-stimulated peritoneal macrophages. Cell Signal. 2003;15:299‒306.
   Web of Science ®Google Scholar
• Hu W, Fang L, Ni R, et al. Changing trends in the disease burden of non-melanoma skin cancer globally from 1990 to 2019 and its predicted level in 25 years. BMC Cancer. 2022;22:836.
   PubMed Web of Science ®Google Scholar
• McGettigan S. Dabrafenib: a new therapy for use in BRAF-mutated metastatic melanoma. J Adv Pract Oncol. 2014;5:211‒215.
   PubMedGoogle Scholar
• Manchado E, Huang CH, Tasdemir N, et al. A pipeline for drug target identification and validation. Cold Spring Harb Symp Quant Biol. 2016;81:257‒267.
   PubMedGoogle Scholar
• Chou YP, Lin YK, Chen CH, et al. Recent advances in polymeric nanosystems for treating cutaneous melanoma and its metastasis. Curr Pharm Design. 2017;23:5301–5314. DOI:10.2174/1381612823666170710121348.
   PubMed Web of Science ®Google Scholar
• Zhang X, Cai A, Gao Y, et al. Treatment of melanoma by nano-conjugate-delivered Wee1 siRNA. Mol Pharm. 2021;18:3387–3400.
   PubMedGoogle Scholar
• Labala S, Jose A, Venuganti VV. Transcutaneous iontophoretic delivery of STAT3 siRNA using layer-by-layer chitosan coated gold nanoparticles to treat melanoma. Colloids Surf B Biointerfaces. 2016;146:188–197.
   PubMed Web of Science ®Google Scholar
• Chen Y, Bathula SR, Yang Q, et al. Targeted nanoparticles deliver siRNA to melanoma. J Invest Dermatol. 2010;130:2790–2798.
   PubMed Web of Science ®Google Scholar
• Reddy TL, Garikapati KR, Reddy SG, et al. Simultaneous delivery of paclitaxel and Bcl-2 siRNA via Ph-sensitive liposomal nanocarrier for the synergistic treatment of melanoma. Sci Rep. 2016;6:35223.
   PubMed Web of Science ®Google Scholar
• Li C, Han X. Melanoma cancer immunotherapy using PD-L1 siRNA and imatinib promotes cancer-immunity cycle. Pharm Res. 2020;37:109.
   PubMed Web of Science ®Google Scholar
• Ehexige E, Bao M, Bazarjav P, et al. Silencing of STAT3 via peptidomimetic LNP-mediated systemic delivery of RNAi downregulates PD-L1 and inhibits melanoma growth. Biomolecules. 2020;10:285.
   PubMed Web of Science ®Google Scholar
• Wang Y, Luo YL, Chen YF, et al. Dually regulating the proliferation and the immune microenvironment of melanoma via nanoparticle-delivered siRNA targeting onco-immunologic CD155. Biomater Sci. 2020;8:6683–6694.
   PubMed Web of Science ®Google Scholar
• Ruan W, Zhai Y, Yu K, et al. Coated microneedles mediated intradermal delivery of octaarginine/BRAF siRNA nanocomplexes for anti-melanoma treatment. Int J Pharm. 2018;553:298–309.
   PubMedGoogle Scholar
• Fico A, Alfano D, Valentino A, et al. C-Myc modulation: a key role in melanoma drug response. Cancer Biol Ther. 2015;16:1375–1386.
   PubMed Web of Science ®Google Scholar
• Gao Y, Chen X, Tian T, et al. A lysosome-activated tetrahedral nanobox for encapsulated siRNA delivery. Adv Mater. 2022;34:e2201731.
   PubMed Web of Science ®Google Scholar
• Li J, Yao Y, Wang Y, et al. Modulation of the crosstalk between Schwann cells and macrophages for nerve regeneration: a therapeutic strategy based on a multifunctional tetrahedral framework nucleic acids system. Adv Mater. 2022;34:e2202513.
   PubMed Web of Science ®Google Scholar
• Ehexige E, Ganbold T, Yu X, et al. Design of peptidomimetic functionalized cholesterol based lipid nanoparticles for efficient delivery of therapeutic nucleic acids. Molecules. 2019;24:3413.
   PubMed Web of Science ®Google Scholar
• Inozume T, Yaguchi T, Furuta J, et al. Melanoma cells control antimelanoma CTL responses via interaction between TIGIT and CD155 in the effector phase. J Invest Dermatol. 2016;136:255–263.
   PubMed Web of Science ®Google Scholar
• Padmakumari RG, Sherly CD, Ramesan RM. Therapeutic delivery of nucleic acids for skin wound healing. Ther Deliv. 2022;13:339–358.
   PubMed Web of Science ®Google Scholar
• Liu Q, Zhang Y, Huang J, et al. Mesoporous silica-coated silver nanoparticles as ciprofloxacin/siRNA carriers for accelerated infected wound healing. J Nanobiotechnol. 2022;20:386.
   PubMed Web of Science ®Google Scholar
• Shaabani E, Sharifiaghdam M, Lammens J, et al. Increasing angiogenesis factors in hypoxic diabetic wound conditions by siRNA delivery: additive effect of LbL-gold nanocarriers and desloratadine-induced lysosomal escape. Int J Mol Sci. 2021;22:9216.
   PubMed Web of Science ®Google Scholar
• Li N, Luo HC, Yang C, et al. Cationic star-shaped polymer as an siRNA carrier for reducing MMP-9 expression in skin fibroblast cells and promoting wound healing in diabetic rats. Int J Nanomed. 2014;9:3377–3387.
   PubMed Web of Science ®Google Scholar
• Rabbani PS, Zhou A, Borab ZM, et al. Novel lipoproteoplex delivers Keap1 siRNA based gene therapy to accelerate diabetic wound healing. Biomaterials. 2017;132:1–15.
   PubMed Web of Science ®Google Scholar
• Rosli NA, Teow YH, Mahmoudi E. Current approaches for the exploration of antimicrobial activities of nanoparticles. Sci Technol Adv Mater. 2021;22:885–907.
   PubMed Web of Science ®Google Scholar
• Coentro JQ, Pugliese E, Hanley G, et al. Current and upcoming therapies to modulate skin scarring and fibrosis. Adv Drug Deliv Rev. 2019;146:37–59.
   PubMed Web of Science ®Google Scholar
• Morry J, Ngamcherdtrakul W, Gu S, et al. Dermal delivery of HSP47 siRNA with NOX4-modulating mesoporous silica-based nanoparticles for treating fibrosis. Biomaterials. 2015;66:41–52.
   PubMed Web of Science ®Google Scholar
• Kang S, Kim J, Ahn M, et al. Won C.RNAi nanotherapy for fibrosis: highly durable knockdown of CTGF/CCN-2 using siRNA-DegradaBALL (LEM-S401) to treat skin fibrotic diseases. Nanoscale. 2020;12:6385–6393.
   PubMed Web of Science ®Google Scholar
• Wang M, Han Y, Yu X, et al. Upconversion nanoparticle powered microneedle patches for transdermal delivery of siRNA. Adv Healthc Mater. 2020;9:e1900635.
   PubMed Web of Science ®Google Scholar
• Chu H, Wu T, Wu W, et al. Involvement of collagen-binding heat shock protein 47 in scleroderma-associated fibrosis. Protein Cell. 2015;6:589–598.
   PubMed Web of Science ®Google Scholar
• Guo S, Li H, Ma M, et al. Size, shape, and sequence-dependent immunogenicity of RNA nanoparticles. Mol Ther Nucleic Acids. 2017;9:399–408.
   PubMedGoogle Scholar
• Guan CM, Chinen AB, Ferrer JR, et al. Impact of sequence specificity of spherical nucleic acids on macrophage activation in vitro and in vivo. Mol Pharm. 2019;16:4223–4229.
   PubMedGoogle Scholar